Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma.

Stephen G NoorduynKarissa JohnstonKathy OsenenkoNiroshan SriskandarajahAlain Gendron Stefan D Baral

Published in: ERJ open research (2021)

Within 1 year, 15% of Canadian patients with severe asthma discontinue benralizumab. The reasons for discontinuation are not yet characterised. https://bit.ly/3kaRDlp.

Keyphrases

chronic obstructive pulmonary disease
lung function
early onset
chronic rhinosinusitis
cystic fibrosis